We forecast one to two GLP-1 launches annually starting in 2026, with the first oral entrant expected by 2027
Phase I/II trial of intranasal glutathione in Parkinsons disease patients
The costs of the treatment may vary depending on factors such as the treatment area and the amount of product needed
Conversely, inhibitory neurotransmission to cardiac vagal neurons is strongly tied to respiratory inputs
Furthermore, sleep in Drosophila has all the behavioral characteristics of mammalian sleep
A limitation with the use of GLUTag cells, as well as other models for epithelial cells, is that the cells have lost their polarization, which may affect the amino acid sensing mechanisms, as different amino acid transporters are situated on the apical compared to the basolateral membrane [28]